Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Not yet recruiting 1

Sponsor Class

OTHER 13NIH 7NETWORK 1INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

CNS 1

Conditions

Head and Neck Neoplasms 5Stomatitis 3Squamous Cell Carcinoma of Head and Neck 2Prostatic Neoplasms 1Neoplasms 1Nasopharyngeal Carcinoma 1Mucositis 1Mouth Neoplasms 1Lung Neoplasms 1Laryngeal Diseases 1Glioblastoma 1Carcinoma, Squamous Cell 1Carcinoma, Non-Small-Cell Lung 1Camurati-Engelmann Syndrome 1

Interventions

Temozolomide 94Radiotherapy 40Bevacizumab 40Lomustine 21Radiation 18Surgical Procedures, Operative 10Carboplatin 9pembrolizumab 8Nivolumab 8Carmustine 8Irinotecan 7IL13-PE38 6Granulocyte-Macrophage Colony-Stimulating Factor 6Flucytosine 6Cyclophosphamide 6ABT-414 6vocimagene amiretrorepvec 5depatuxizumab mafodotin 5Valacyclovir 5Drug Therapy 5veledimex 4sargramostim 4enzastaurin 4NVP-BKM120 4Gemcitabine 4Dianhydrogalactitol 4Chlorotoxin 4Aminolevulinic Acid 4verubulin 3selinexor 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
INDUSTRY × Glioblastoma × Radiotherapy, Intensity-Modulated × Clear all
NCT04373785 2025-10-21

NG101m Adjuvant Therapy in Glioblastoma Patients

NeuGATE Theranostics

Phase 1/2 Not yet recruiting
52 enrolled
CNS

Glioblastoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡